GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Research & Development

PRQR (ProQR Therapeutics NV) Research & Development : $36.56 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. ProQR Therapeutics NV's Research & Development for the three months ended in Sep. 2024 was $10.45 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $36.56 Mil.

ProQR Therapeutics NV Research & Development Historical Data

The historical data trend for ProQR Therapeutics NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Research & Development Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.66 46.39 47.71 53.89 27.42

ProQR Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.81 8.43 10.09 7.59 10.45

ProQR Therapeutics NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV  (NAS:PRQR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ProQR Therapeutics NV Research & Development Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

ProQR Therapeutics NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Research & Development
Comparable Companies
PRLD MNOV CDXC ANIX GMDA NKTX INO IFRX VXRT ABEO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0PQ:Germany
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
Website
https://www.proqr.com
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.